SCHEDULE 13G: Armistice Capital and Steven Boyd Disclose 9.99% Stake in GeoVax Labs

Investment firm Armistice Capital, LLC and its managing member Steven Boyd have disclosed a 9.99% beneficial ownership stake in GeoVax Labs, Inc., holding 1,612,729 shares of common stock.

Summary

• Armistice Capital, LLC and Steven Boyd (collectively, the "Reporting Persons") have filed a Schedule 13G, indicating their beneficial ownership in GeoVax Labs, Inc.
• The Reporting Persons collectively beneficially own 1,612,729 shares of GeoVax Labs, Inc. common stock.
• This ownership represents 9.99% of the total outstanding common stock of GeoVax Labs, Inc.
• Armistice Capital, LLC acts as the investment manager for Armistice Capital Master Fund Ltd., which is the direct holder of these shares.
• Steven Boyd, as the managing member of Armistice Capital, LLC, is also deemed to beneficially own these securities.
• The filing certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or future prospects.

Positives

• The disclosure of a significant institutional stake (9.99%) by Armistice Capital, LLC may signal confidence or strategic interest in GeoVax Labs, Inc. from a notable investment firm.
• The filing indicates that the investment is passive, suggesting no immediate intent to disrupt the company's operations or management.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may be viewed positively, potentially increasing investor confidence or signaling future interest in the company.

Key Dates

Keywords

GeoVax Labs, Armistice Capital, Steven Boyd, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing